Insilico Medicine (HKG:3696) said ISM6331 received fast-track designation from the U.S. Food and Drug Administration for the treatment of adult patients with unresectable malignant pleural mesothelioma, according to a Wednesday filing with the Hong Kong Stock Exchange.
The company said the designation covers adult patients with unresectable malignant pleural mesothelioma.
Shares of the biopharmaceutical company were down 4% in recent trade.